11-107
Showing 1 - 25 of >10,000
Hidradenitis Suppurativa Trial in Worldwide (Imsidolimab, Placebo Solution)
Active, not recruiting
- Hidradenitis Suppurativa
- Imsidolimab
- Placebo Solution
-
Birmingham, Alabama
- +33 more
Sep 19, 2022
Healthy Volunteers Trial in London (Amphetamine, TAK -041, [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO))
Completed
- Healthy Volunteers
- Amphetamine
- +2 more
-
London, United KingdomHammersmith Medicines Research
Mar 17, 2021
Hypertension Trial in Cincinnati (baxdrostat (formerly CIN-107) oral solution)
Completed
- Hypertension
- baxdrostat (formerly CIN-107) oral solution
-
Cincinnati, OhioMedpace
Jul 18, 2023
Advanced Solid Tumor Trial in Beijing (YK0901 cells)
Not yet recruiting
- Advanced Solid Tumor
- YK0901 cells
-
Beijing, ChinaDepartment of GI Oncology, Peking University Cancer Hospital
Jun 27, 2023
Nasopharyngeal Carcinoma Trial (PK Blood Collection, CAR, TCR)
Not yet recruiting
- Nasopharyngeal Carcinoma
- PK Blood Collection
- +2 more
- (no location specified)
Nov 1, 2022
Pemphigus Vulgaris, Pemphigus Foliaceus Trial in Worldwide (efgartigimod PH20 SC, prednisone)
Recruiting
- Pemphigus Vulgaris
- Pemphigus Foliaceus
- efgartigimod PH20 SC
- prednisone
-
Birmingham, Alabama
- +120 more
Dec 22, 2022
Mild Cognitive Impairment, Dementia Trial in United States (CST-2032, matching for CST-2032, CST-107, matching for CST-107)
Recruiting
- Mild Cognitive Impairment
- Dementia
- CST-2032, matching placebo for CST-2032, CST-107, matching placebo for CST-107
-
Scottsdale, Arizona
- +14 more
Jan 4, 2023
Bacterial Vaginosis, Bacterial Infections, Bacterial Vaginosis | Vaginal | Microbiology Trial (Preforpro, Placebo)
Not yet recruiting
- Bacterial Vaginosis
- +3 more
- Preforpro
- Placebo
- (no location specified)
Oct 19, 2022
Uncontrolled Hypertension, Chronic Kidney Diseases Trial in United States (CIN-107, Placebo)
Recruiting
- Uncontrolled Hypertension
- Chronic Kidney Diseases
- CIN-107
- Placebo
-
Birmingham, Alabama
- +45 more
Aug 10, 2022
Primary Aldosteronism, Hyperaldosteronism Trial in United States (CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing)
Recruiting
- Primary Aldosteronism
- Hyperaldosteronism
- CIN-107 2 mg dosing
- +2 more
-
Los Angeles, California
- +7 more
Feb 1, 2023
Hypertension Trial in Cincinnati (CIN-107, Matching Placebo)
Completed
- Hypertension
- CIN-107
- Matching Placebo
-
Cincinnati, OhioMedpace Clinical Pharmacology Unit
Aug 12, 2022
Pemphigus Vulgaris, Pemphigus Foliaceus Trial in Worldwide (biological, other, drug)
Recruiting
- Pemphigus Vulgaris
- Pemphigus Foliaceus
- efgartigimod PH20 SC
- +2 more
-
Birmingham, Alabama
- +130 more
Dec 22, 2022
Adult Acute Lymphoblastic Leukemia in Remission, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1,
Completed
- Adult Acute Lymphoblastic Leukemia in Remission
- +9 more
- Cyclosporine
- +9 more
-
Denver, Colorado
- +2 more
Jan 17, 2020
Facial Papulopustular Rosacea Trial in United States (FMX103 minocycline foam 1.5%, Vehicle foam)
Completed
- Facial Papulopustular Rosacea
- FMX103 minocycline foam 1.5%
- Vehicle foam
-
Tucson, Arizona
- +53 more
Jan 27, 2021
Healthy Volunteers, Norovirus Trial in Belgium, United States (NoV Vaccine)
Completed
- Healthy Volunteers
- Norovirus
- NoV Vaccine
-
Birmingham, Alabama
- +10 more
Nov 7, 2022
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's
Active, not recruiting
- Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
- CST-103, CST-107, matching placebo
-
Sydney, New South Wales, Australia
- +6 more
Jun 1, 2022
Superficial Bladder Cancer Trial in United States (ADSTILADRIN)
Active, not recruiting
- Superficial Bladder Cancer
- ADSTILADRIN
-
Gilbert, Arizona
- +33 more
Dec 2, 2022
Freezing of Gait Symptoms in Parkinson's Disease Trial in Sydney (CST-103, CST-107, matching )
Not yet recruiting
- Freezing of Gait Symptoms in Parkinson's Disease
- CST-103, CST-107, matching placebo
-
Sydney, New South Wales, AustraliaThe University of Sydney
Jun 1, 2022